Hepatitis C News

VIENNA — A real-world analysis of Mavyret for hepatitis C showed patients with key comorbidities such as psychiatric disorders and substance abuse achieved high rates of sustained virologic response with improvements in patient-reported outcomes, according to a presentation at the International Liver Congress 2019.

For the treatment of chronic hepatitis C genotype 1 through 6 infections, glecaprevir and pibrentasvir demonstrated safety and efficacy in patients with compensated liver disease, including those with chronic kidney disease stage 4 or 5, according to results pooled from nine phase 2 and 3 trials.

Hearts from donors with hepatitis C virus are safe for transplantation, and the recipients respond to HCV treatment after transplantation, according to data presented at the Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation.

Results from a recent study showed that a multifaceted intervention including provider and patient education, electronic medical record-enabled best practice alert, and increased hepatitis C treatment capacity significantly increased hepatitis C screening.

Study findings published today in The New England Journal of Medicine demonstrated the safety of transplanting hearts and lungs from hepatitis C-positive donors into HCV-negative recipients.

The Louisiana Department of Health selected Asegua Therapeutics, a subsidiary of Gilead Sciences, as their pharmaceutical partner in a “subscription style” payment plan designed to provide state residents with access to hepatitis C treatment, according to a press release from the department.

SFA Therapeutics received second patent approval for its liver disease therapy SFA001, according to a press release.

According to a study published in Hepatology, small dense LDL cholesterol independently predicted cardiovascular disease events among liver transplant recipients, according to a study published in Hepatology.

The U.S. Department of Veterans Affairs announced that it is on track to eliminate hepatitis C in all veterans willing and able to receive treatment within a timeframe of two months, according to a press release from the office.

Twelve weeks of combination Sovaldi and NS5A inhibitors without ribavirin was a reliable therapy with high rates of sustained virologic response for recurrent hepatitis C after liver transplantation, according to a study published in Hepatology.